Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Jun;189(6):e248-e251.
doi: 10.1111/bjh.16679. Epub 2020 Apr 27.

LyRIC indeterminate response and Immune-mediated pseudoprogression of diffuse large B-cell lymphoma following polatuzumab-based salvage therapy

Alexander T J Lee  1 , Ayoma D Attygale  1 , Rajaei K Sharma  2 , Sunil Iyengar  1 , Dima El-Sharkawi  1 , Ian Chau  1 , Katherine M Vroobel  1 , Nicos Fotiadis  1 , Nasir Khan  1 , Nicholas Butterfield  1 , Andrew Wotherspoon  1 , David Cunningham  1 , Bhupinder Sharma  1
Affiliations
Comment

LyRIC indeterminate response and Immune-mediated pseudoprogression of diffuse large B-cell lymphoma following polatuzumab-based salvage therapy

Alexander T J Lee et al. Br J Haematol. 2020 Jun.
No abstract available

Keywords: diffuse large B cell lymphoma; polatuzumab; pseudo-progression.

PubMed Disclaimer

Comment on

  • Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, Assouline S, Kim TM, Kim WS, Ozcan M, Hirata J, Penuel E, Paulson JN, Cheng J, Ku G, Matasar MJ. Sehn LH, et al. J Clin Oncol. 2020 Jan 10;38(2):155-165. doi: 10.1200/JCO.19.00172. Epub 2019 Nov 6. J Clin Oncol. 2020. PMID: 31693429 Free PMC article. Clinical Trial.

References

    1. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2019;38(2):155-65.
    1. Polatuzumab Vedotin Approved for DLBCL. Cancer Discov. 2019;9(8):OF2. https://doi.org/10.1158/2159-8290.CD-NB2019-076.
    1. Shingleton JR, Dave SS. Polatuzumab vedotin: honing in on relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38(2):166-8. https://doi.org/10.1200/JCO.19.02587.
    1. Cunningham J, Iyengar S, Sharma B. Evolution of lymphoma staging and response evaluation: current limitations and future directions. Nat Rev Clin Oncol. 2017;14(10):631-45. https://doi.org/10.1038/nrclinonc.2017.78.
    1. Han HS, Escalón M, Hsiao B, et al. High incidence of false-positive PET scans in patients with aggressive non-Hodgkin’s lymphoma treated with rituximab-containing regimens. Ann Oncol. 2009;20(2):309-18. https://doi.org/10.1093/annonc/mdn629.

LinkOut - more resources